Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to $192000.0.

  • Cartesian Therapeutics' Amortizatization of Intangibles fell 7059.72% to $192000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 4495.99%. This contributed to the annual value of $2.4 million for FY2024, which is 3893.96% up from last year.
  • Cartesian Therapeutics' Amortizatization of Intangibles amounted to $192000.0 in Q3 2025, which was down 7059.72% from $187000.0 recorded in Q2 2025.
  • Cartesian Therapeutics' Amortizatization of Intangibles' 5-year high stood at $671000.0 during Q4 2024, with a 5-year trough of $184000.0 in Q1 2025.
  • Over the past 5 years, Cartesian Therapeutics' median Amortizatization of Intangibles value was $339000.0 (recorded in 2022), while the average stood at $379473.7.
  • In the last 5 years, Cartesian Therapeutics' Amortizatization of Intangibles soared by 4977.06% in 2024 and then plummeted by 7059.72% in 2025.
  • Cartesian Therapeutics' Amortizatization of Intangibles (Quarter) stood at $287000.0 in 2021, then skyrocketed by 41.81% to $407000.0 in 2022, then rose by 16.95% to $476000.0 in 2023, then skyrocketed by 40.97% to $671000.0 in 2024, then crashed by 71.39% to $192000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $192000.0 for Q3 2025, versus $187000.0 for Q2 2025 and $184000.0 for Q1 2025.